Targeting EGFR and ERBB3 in lung cancer patients: Clinical outcomes in a phase I trial of MM-121 in combination with erlotinib.

被引：0
|
作者：
Sequist, Lecia V.
Modiano, Manuel R.
Rixe, Olivier
Jackman, David Michael
Andreas, Karen
Pearlberg, Joseph
Moyo, Victor M.
Harb, Wael A.
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[2] Arizona Clin Res Ctr, Tucson, AZ USA
[3] Univ Cincinnati, Cincinnati, OH USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Merrimack Pharmaceut, Cambridge, MA USA
[6] Sanofi Oncol, Cambridge, MB, Canada
[7] Horizon Oncol Ctr, Lafayette, IN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7556
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Targeting ErbB receptor interactions: A phase I trial of trastuzumab and erlotinib in metastatic HER2+breast cancer
    Britten, CD
    Pegram, M
    Rosen, P
    Finn, RS
    Wax, A
    Bosserman, L
    Gordon, L
    Lin, LS
    Mass, R
    Slamon, DJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 206S - 206S
  • [22] Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer
    Sequist, Lecia, V
    Gray, Jhanelle Elaine
    Harb, Wael A.
    Lopez-Chavez, Ariel
    Doebele, Robert C.
    Modiano, Manuel R.
    Jackman, David Michael
    Baggstrom, Maria Quintos
    Atmaca, Akin
    Felip, Enriqueta
    Provencio, Mariano
    Cobo, Manuel
    Adiwijaya, Bambang
    Kuesters, Geoffrey
    Kamoun, Walid S.
    Andreas, Karen
    Pipas, J. Marc
    Santillana, Sergio
    Cho, Byoung Chul
    Park, Keunchil
    Shepherd, Frances A.
    ONCOLOGIST, 2019, 24 (08): : 1095 - 1102
  • [23] Randomized Phase 2 Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer
    Sequist, L.
    Gray, J.
    Harb, W.
    Doebele, R.
    Modiano, M.
    Jackman, D.
    Baggstrom, M.
    Atmaca, A.
    Felip, E.
    Provencio, M.
    Cobo Dols, M.
    Adiwijaya, B.
    Kuesters, G.
    Kamoun, W.
    Andreas, K.
    Pipas, J.
    Santillana, S.
    Cho, B. C.
    Park, K.
    Shepherd, F.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S596 - S596
  • [24] A phase Ib/II study of afatinib in combination with nimotuzumab in non-small cell lung cancer patients with acquired resistance to gefitinib or erlotinib.
    Ahn, Myung-Ju
    Lee, Ji Yun
    Sun, Jong-Mu
    Ku, Bo Mi
    Koh, Jiae
    Lim, Sung Hee
    Lee, Min-Young
    Kim, Haesu
    Ahn, Jin Seok
    Park, Keunchil
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [25] Phase I/ii And Pharmacological Clinical Study Of Combination Chemotherapy With Irinotecan And Erlotinib For Recurrent Lung Cancer
    Okimoto, T.
    Hotta, T.
    Koba, N.
    Nishikawa, E.
    Maehara, M.
    Miura, K.
    Karino, F.
    Iwamoto, S.
    Tsubata, Y.
    Hamaguchi, S.
    Honda, T.
    Mitsuhiro, T.
    Ohe, M.
    Sutani, A.
    Kuraki, T.
    Takeyama, H.
    Hamada, A.
    Isobe, T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [26] The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells
    Huang, Jingcao
    Wang, Shuiliang
    Lyu, Hui
    Cai, Bo
    Yang, XiaoHe
    Wang, Jianxiang
    Liu, Bolin
    MOLECULAR CANCER, 2013, 12
  • [27] A PHASE I / II TRIAL OF THE HDAC INHIBITOR BELINOSTAT IN COMBINATION WITH ERLOTINIB IN PATIENTS WITH NON-SMALL CELL LUNG CANCER.
    Andersen, Jon L.
    Holm, Bente
    Rasmussen, Trine S.
    Mellemgaard, Anders
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1201 - S1202
  • [28] Phase I Trial of Carboplatin and Etoposide in Combination with Panobinostat in Patients with Lung Cancer
    Tarhini, Ahmad A.
    Zahoor, Harts
    Mclaughlin, Brian
    Gooding, William E.
    Schmitz, John C.
    Siegfried, Jill M.
    Socinski, Mark A.
    Argiris, Athanassios
    ANTICANCER RESEARCH, 2013, 33 (10) : 4475 - 4481
  • [29] The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells
    Jingcao Huang
    Shuiliang Wang
    Hui Lyu
    Bo Cai
    XiaoHe Yang
    Jianxiang Wang
    Bolin Liu
    Molecular Cancer, 12
  • [30] A phase I / I to find optimal dose of Erlotinib(RE) in only patients with lung cancer harboring EGFR sensitive mutations
    Yuichiro, Takeda
    Naoki, Ishizuka
    Kazumi, Sano
    Haruhito, Sugiyama
    CANCER SCIENCE, 2018, 109 : 901 - 901
12345